Dodge & Cox Has $2.78 Million Stake in Pfizer Inc. $PFE

Dodge & Cox decreased its stake in Pfizer Inc. (NYSE:PFE) by 1.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 109,710 shares of the biopharmaceutical company’s stock after selling 1,850 shares during the period. Dodge & Cox’s holdings in Pfizer were worth $2,780,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter worth about $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth about $28,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.3%

NYSE:PFE opened at $25.8250 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $146.83 billion, a PE ratio of 13.74, a PEG ratio of 0.92 and a beta of 0.52. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock has a 50-day simple moving average of $24.70 and a 200 day simple moving average of $24.40.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analyst Ratings Changes

Several equities research analysts have issued reports on PFE shares. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Wolfe Research increased their price target on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a report on Wednesday, April 30th. HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America increased their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.